Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33.

Article  PubMed  Google Scholar 

Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275–89.

Article  PubMed  PubMed Central  Google Scholar 

Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;15(366):l2381.

Article  Google Scholar 

Dimitriadis E, Rolnik DL, Zhou W, Estrada-Gutierrez G, Koga K, Francisco RPV, et al. Pre-eclampsia Nat Rev Dis Primers. 2023;9(1):8.

Article  PubMed  Google Scholar 

Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2).

Hackshaw A, Morris JK, Boniface S, Tang J-L, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;24(360):j5855.

Article  Google Scholar 

•Moufarrej MN, Bianchi DW, Shaw GM, Stevenson DK, Quake SR. Noninvasive prenatal testing using circulating DNA and RNA: advances, challenges, and possibilities. Annu Rev Biomed Data Sci. 2023;6:397–418. This review details the advances in noninvasive prenatal testing in the past decade and provides a lens to assess the impact of liquid biopsy testing on prenatal care more generally.

•Rasmussen M, Reddy M, Nolan R, Camunas-Soler J, Khodursky A, Scheller NM, et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022;601(7893):422–7. This study along with Moufarrej et al. (2022) demonstrates the utility of cell-free RNA to predict risk of preeclampsia. This work focused on cell-free RNA’s utility as a predictor in the early second trimester.

•Moufarrej MN, Vorperian SK, Wong RJ, Campos AA, Quaintance CC, Sit RV, et al. Early prediction of preeclampsia in pregnancy with cell-free RNA. Nature. 2022;602(7898):689–94. This study along with Rasmussen et al. (2022) demonstrates the utility of cell-free RNA to predict risk of preeclampsia. This work focused on cell-free RNA’s utility as a predictor in across gestation and especially in the first trimester.

•De Borre M, Che H, Yu Q, Lannoo L, De Ridder K, Vancoillie L, et al. Cell-free DNA methylome analysis for early preeclampsia prediction. Nat Med. 2023;28. This study demonstrates the utility of cell-free DNA to predict risk of early-onset preeclampsia.

Ngo TTM, Moufarrej MN, Rasmussen M-LH, Camunas-Soler J, Pan W, Okamoto J, et al. Noninvasive blood tests for fetal development predict gestational age and preterm delivery. Science. 2018;360(6393):1133–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan W, Ngo TTM, Camunas-Soler J, Song C-X, Kowarsky M, Blumenfeld YJ, et al. Simultaneously monitoring immune response and microbial infections during pregnancy through plasma cfRNA sequencing. Clin Chem. 2017;63(11):1695–704.

Article  CAS  PubMed  Google Scholar 

Linthorst J, Welkers MRA, Sistermans EA. Clinically relevant DNA viruses in pregnancy. Prenat Diagn. 2022;15.

Linthorst J, Baksi MMM, Welkers MRA, Sistermans EA. The cell-free DNA virome of 108,349 Dutch pregnant women. Prenat Diagn. 2022;11.

Chesnais V, Ott A, Chaplais E, Gabillard S, Pallares D, Vauloup-Fellous C, et al. Using massively parallel shotgun sequencing of maternal plasmatic cell-free DNA for cytomegalovirus DNA detection during pregnancy: a proof of concept study. Sci Rep. 2018;8(1):4321.

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Huang S, Chen F, Zhao L, Yuan Y, Francis SS, et al. Genomic analyses from non-invasive prenatal testing reveal genetic associations, patterns of viral infections, and chinese population history. Cell. 2018;175(2):347-359.e14.

Article  CAS  PubMed  Google Scholar 

Camunas-Soler J, Gee EPS, Reddy M, Mi JD, Thao M, Brundage T, et al. Predictive RNA profiles for early and very early spontaneous preterm birth. Am J Obstet Gynecol. 2022;227(1):72.e1-72.e16.

Article  PubMed  Google Scholar 

Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141–6.

Article  PubMed  Google Scholar 

Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110-120.e6.

Article  CAS  PubMed  Google Scholar 

Roberts JM, King TL, Barton JR, Beck S, Bernstein IM, Buck TE, et al. Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up. Am J Obstet Gynecol. 2023;229(3):193–213.

Article  PubMed  Google Scholar 

Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017;20(5):307.

Article  Google Scholar 

Organization WH. Trends in maternal mortality 2000 to 2017: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division: executive summary. 2019.

Fink DA, Kilday D, Cao Z, Larson K, Smith A, Lipkin C, et al. Trends in maternal mortality and severe maternal morbidity during delivery-related hospitalizations in the United States, 2008 to 2021. JAMA Netw Open. 2023;6(6):e2317641.

Article  PubMed  PubMed Central  Google Scholar 

Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83.

Article  CAS  PubMed  Google Scholar 

Thadhani R, Lemoine E, Rana S, Costantine MM, Calsavara VF, Boggess K, et al. Circulating angiogenic factor levels in hypertensive disorders of pregnancy. NEJM evid. 2022;9.

Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008;32(6):732–9.

Article  CAS  PubMed  Google Scholar 

Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol. 2022;226(2S):S1071–S1097.e2.

Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8–15.

Article  PubMed  Google Scholar 

O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756–60.

Article  PubMed  Google Scholar 

Poon LCY, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11–13 weeks’ gestation. Fetal Diagn Ther. 2012;31(1):42–8.

Article  CAS  PubMed  Google Scholar 

Velauthar L, Plana MN, Kalidindi M, Zamora J, Thilaganathan B, Illanes SE, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound Obstet Gynecol. 2014;43(5):500–7.

Article  CAS  PubMed  Google Scholar 

Oliveira N, Magder LS, Blitzer MG, Baschat AA. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol. 2014;44(3):279–85.

Article  CAS  PubMed  Google Scholar 

Chaemsaithong P, Pooh RK, Zheng M, Ma R, Chaiyasit N, Tokunaka M, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. Am J Obstet Gynecol. 2019;221(6):650.e1-650.e16.

Article  PubMed  Google Scholar